Disseminated cysticercosis and Kaposi sarcoma in a child with HIV/AIDS: A case report

David W. McCormick1††, Jason M. Bacha1,2,3†, Nader K. El-Mallawany4, Carrie L. Kovarik5, J. S. Slone4 and Liane R. Campbell1,2,3

Abstract

Background: Clinical manifestations of extraneural infection with the pork tapeworm *Taenia solium* typically affect the muscles, eyes, alimentary canal, and/or subcutaneous tissues. Children living with HIV are at increased risk for more widespread and severe manifestations of food-borne opportunistic infections, including *T. solium*, due to fluctuating levels of immunosuppression. We present a case of disseminated *T. solium* in a HIV-positive child with Kaposi sarcoma living in Tanzania with cysticercosis presenting as widespread subcutaneous nodules.

Case presentation: A 4-year-old HIV-positive boy in Southern Tanzania presented for evaluation of > 30 violaceous skin lesions, few subcutaneous nodules, and a circumferential violaceous penile lesion which rapidly grew after initiation of ART. The patient was clinically diagnosed with Kaposi sarcoma and started on chemotherapy with bleomycin, vincristine, and doxorubicin. He completed 10 cycles of chemotherapy, with full resolution of the violaceous skin and penile lesions but persistence of his subcutaneous nodules, thus paclitaxel was added. After 12 additional cycles of paclitaxel, his subcutaneous nodules enlarged, and biopsy of a scapular subcutaneous nodule was performed. Histopathology revealed a cystic structure with a central larval scolex and serrated spiral canal consistent with *T. solium*, which confirmed a diagnosis of disseminated cysticercosis. He completed a 10-day course of praziquantel and albendazole with resolution of the subcutaneous nodules.

Conclusions: Disseminated cysticercosis is an unusual opportunistic infection which can present as subcutaneous nodules without other typical cysticercosis symptoms. Immunosuppression – from HIV and/or chemotherapy – may unmask cysticercosis in children in endemic regions and result in more severe manifestations of this disease. Cysticercosis should remain on a clinician’s differential for subcutaneous nodules, especially in children living with HIV. Cysticercosis can mimic Kaposi sarcoma, and histopathology is essential to accurately diagnose and manage patients with concerning skin lesions.

Keywords: Kaposi sarcoma, Cysticercosis, *Taenia solium*, HIV, AIDS, Opportunistic infection
Background
Cysticercosis is an infection with the larval form of Taenia solium, the pork tapeworm. Cysticercosis is transmitted through fecal contamination of food or water or autoinfection, and persons with taeniasis (the intestinal form) serve as the reservoir. Poor food preparation and hand hygiene increases the risk of cysticercosis [1]. While mild or asymptomatic intestinal infection commonly occurs following ingestion of contaminated pork, there are two important, more severe clinical manifestations of cysticercosis that can occur following ingestion of food or water contaminated with cysts, depending on the site of larval encystation. Neurocysticercosis (NCC) refers to encystation of cysticerci within the brain parenchyma or subarachnoid space, and is the leading cause of seizures in low- and middle-income countries (LMIC) [2]. Disseminated cysticercosis (DC) refers to cysticerci migrating to and encystation in skeletal muscle, cardiac muscle, eyes, and/or subcutaneous tissues.

Cysticercosis is one of the most prevalent helminth infections globally, with an estimated 370,000 persons affected by NCC [3]. Data specific to sub-Saharan Africa (SSA) are limited; however, regional SSA data suggest a higher prevalence than in South America and the Indian subcontinent [4], and a major cause of disability-adjusted life-years in SSA [3]. In Tanzania, recent estimates suggest that approximately 16% of the population have DC or NCC, and 2–5% of the population has taeniasis [5].

Disseminated cysticercosis is an uncommon manifestation of infection with T. solium and most commonly presents as subcutaneous and intramuscular nodules, although any organ can be infected [6–10]. Among people living with HIV, a recent case-control study did not find any association between HIV infection and NCC in Tanzania [11], and to date, no unique relationship between NCC and HIV has been reported [12]. We present a case of disseminated cysticercosis in a HIV positive child being treated for Kaposi sarcoma in Tanzania that presented as widespread subcutaneous lesions following initiation of antiretroviral therapy (ART) and chemotherapy.

Case presentation
An HIV-positive 4-year-old boy presented to clinic for evaluation of worsening skin lesions after starting ART. His absolute (percentage) CD4 count at the time of ART initiation was 32 cells/μL (3%) (Fig. 1), and he was started on ART with zidovudine-lamivudine-nevirapine. Approximately 3 months after ART initiation, he developed > 30 violaceous papules and plaques, a necrotic edematous circumferential plaque on the distal shaft and glans of the penis, and scattered small subcutaneous nodules in his submandibular and cervical regions (Fig. 2, panel a). He was clinically diagnosed with Kaposi sarcoma secondary to the immune reconstitution inflammatory syndrome due to the classic appearance of his skin lesions.

Abbreviations: BV- bleomycin and vincristine; BVD-bleomycin, vincristine, doxorubicin

Fig. 1 Timeline of clinical course from day of presentation showing absolute CD4 count and major clinical events
cutaneous lesions. His ART was shifted to abacavir-lamivudine-lopinavir/ritonavir due to anemia (hemoglobin 7.2 g/dL) and potential activity of protease inhibitors against human herpes virus-8 [13, 14]. He was started on a chemotherapy regimen of bleomycin (15 U/m²) and vincristine (1.4 mg/m²) every 2 weeks. Biopsy was not obtained initially due to logistical and resource constraints.

After five cycles of this chemotherapeutic regimen, doxorubicin (25–35 mg/m²) was added based on failure to achieve complete clinical remission. The patient completed an additional 10 cycles of bleomycin-vincristine-doxorubicin every 3 weeks without complete remission of the violaceous lesions or penile nodule. During the course of chemotherapy, he achieved full virologic suppression and his CD4 count had increased to 265 cells/μL (13%) after 143 days of antiretroviral therapy (Fig. 1). However, his KS lesions continued to persist, and chemotherapy was shifted to monthly paclitaxel. He eventually completed 12 cycles of paclitaxel monotherapy with dexamethasone as a premedication and showed improvement and full resolution of the violaceous skin and penile lesion. However, during this time he developed numerous additional subcutaneous nodules on his trunk, tongue, and extremities that rapidly and progressively increased in size in number (Fig. 2, panel b).

A biopsy was taken for further investigation. Histopathology of the nodule revealed a cystic structure with...
a central larval scolex and serrated spiral canal consistent with *T. solium*, which confirmed the diagnosis of DC (Fig. 3). Additional history taking with the caregiver revealed that the patient and his family consumed pork frequently as a regular part of their diet.

Chemotherapy was stopped and he was treated for DC with albendazole 7.5 mg/kg twice daily and praziquantel 25 mg/kg twice daily for 10 days. Prednisone was administered as an adjunctive treatment to limit the possibility of cerebral edema as NCC could not be ruled out (computed tomography scans of the head were unavailable). He had almost complete resolution of all subcutaneous nodules during his 10-day treatment course (Fig. 2, panel c). All treatment was well-tolerated with minor toxicity (anemia). A small sublingual nodule persisted acutely following treatment, fully resolving several months later. He has not had recurrence of KS or DC after 42 months of follow-up.

**Discussion and conclusions**

Given the limited diagnostic capabilities, it is difficult to determine if the DC in this patient was a complication of primary infection with *T. solium*, or secondary to underlying immunodeficiency secondary to HIV/AIDS, chemotherapy, steroid administration, or reconstitution of the immune system following ART initiation. Infection with HIV has not been associated with increased prevalence of cysticercosis or increased severity of disease; however, prevalence of helminth infections seems to peak with a CD4 count of 200–500 [11, 12, 15]. There is no clear association between HIV infection and cysticercosis [11, 12], and it is difficult to determine if the subcutaneous nodules seen in our patient represent primary infection or unmasking of extant lesions following reconstitution of the immune system.

The presentation of DC following ART and chemotherapy is a reminder that clinicians need to consider DC in the differential for CLHIV living in areas with high burden of cysticercosis and/or other helminthic disease who develop widespread subcutaneous nodules during treatment. The differential diagnosis for cutaneous cestode infections in children in SSA includes sparganosis and echinococcosis, which should be also be considered when an immunocompromised person’s clinical course worsens or fails to improve [16, 17]. Clinicians in endemic regions must be familiar with the signs and symptoms of all forms of *T. solium* endemic regions must be familiar with the signs and symptoms and treatment.

Chemotherapy was stopped and he was treated for DC with albendazole 7.5 mg/kg twice daily and praziquantel 25 mg/kg twice daily for 10 days. Prednisone was administered as an adjunctive treatment to limit the possibility of cerebral edema as NCC could not be ruled out (computed tomography scans of the head were unavailable). He had almost complete resolution of all subcutaneous nodules during his 10-day treatment course (Fig. 2, panel c). All treatment was well-tolerated with minor toxicity (anemia). A small sublingual nodule persisted acutely following treatment, fully resolving several months later. He has not had recurrence of KS or DC after 42 months of follow-up.

**Abbreviations**

ART: Antiretroviral therapy; AIDS: Acquired Immunodeficiency Syndrome; CD4: Cluster of Differentiation 4 cell; CLHIV: Children living with HIV; DC: Disseminated cysticercosis; KS: Kaposi Sarcoma; HIV: Human Immunodeficiency Virus; LMIC: Low- and middle-income countries; NCC: Neurocysticercosis; SSA: Sub-Saharan Africa

**Acknowledgements**

We thank the patient and his family for participation in the case report, and we thank the staff at the Baylor College of Medicine Center of Excellence in Mbeya, Tanzania.

We are grateful to the staff at Baylor College of Medicine Children’s Foundation – Tanzania Centre of Excellence for their relentless dedication to bettering the lives of our patients and families. We would also like to recognize the courage and fortitude of our patients and their families as they survive and thrive despite their diagnosis of HIV.

**Authors’ contributions**

DWM, JMB, and LRC were responsible for data extraction, patient chart review, and creating and writing of the initial manuscript drafts. DWM, JMB, LRC, NE, CLK, and JSS were all involved in the clinical care, treatment, and follow up aspects for the case presented. DWM, JMB, LRC, NE, CLK, and JSS were all involved in reviewing/revising of manuscript drafts, have agreed to be accountable for all aspects of the work, and have given final approval of the final manuscript version to be published.

**Funding**

The authors have no sources of funding to declare.

**Availability of Data and materials**

The data used and/or analysed during this case report are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Approval was obtained from the Mbeya Medical Research and Ethics Committee and the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR) in Tanzania, and the Institutional Review Board, Baylor College of Medicine in Houston, Texas, USA (H-32491). Waiver of patient informed consent was approved by all committees as this retrospective study analyzed only de-identified data.

**Consent for publication**

Waiver of patient informed consent was approved by all committees as this retrospective study analyzed only de-identified data. However, written (and verbal) caregiver consent was obtained from the patient’s parent to take and share photographs for clinical educational purposes during the course of care and treatment at the Baylor Mbeya COE.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Baylor College of Medicine, 1 Baylor Plaza BCM 620, Houston, TX 77030-3411, USA. 2. Baylor International Pediatric AIDS Initiative (BIPAI) at Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, USA.

**Acknowledgements**

We thank the patient and his family for participation in the case report, and we thank the staff at the Baylor College of Medicine Center of Excellence in Mbeya, Tanzania.

We are grateful to the staff at Baylor College of Medicine Children’s Foundation – Tanzania Centre of Excellence for their relentless dedication to bettering the lives of our patients and families. We would also like to recognize the courage and fortitude of our patients and their families as they survive and thrive despite their diagnosis of HIV.

**Authors’ contributions**

DWM, JMB, and LRC were responsible for data extraction, patient chart review, and creating and writing of the initial manuscript drafts. DWM, JMB, LRC, NE, CLK, and JSS were all involved in the clinical care, treatment, and follow up aspects for the case presented. DWM, JMB, LRC, NE, CLK, and JSS were all involved in reviewing/revising of manuscript drafts, have agreed to be accountable for all aspects of the work, and have given final approval of the final manuscript version to be published.

**Funding**

The authors have no sources of funding to declare.

**Availability of Data and materials**

The data used and/or analysed during this case report are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Approval was obtained from the Mbeya Medical Research and Ethics Committee and the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR) in Tanzania, and the Institutional Review Board, Baylor College of Medicine in Houston, Texas, USA (H-32491). Waiver of patient informed consent was approved by all committees as this retrospective study analyzed only de-identified data.

**Consent for publication**

Waiver of patient informed consent was approved by all committees as this retrospective study analyzed only de-identified data. However, written (and verbal) caregiver consent was obtained from the patient’s parent to take and share photographs for clinical educational purposes during the course of care and treatment at the Baylor Mbeya COE.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Baylor College of Medicine, 1 Baylor Plaza BCM 620, Houston, TX 77030-3411, USA. 2. Baylor International Pediatric AIDS Initiative (BIPAI) at Texas Children’s Hospital, Baylor College of Medicine, Houston, TX, USA.

**Baylor College of Medicine Children’s Foundation - Tanzania, Pediatrics, Mbeya, Tanzania. 4. Baylor College of Medicine - Texas Children’s Cancer and Hematology Centers, Houston, TX, USA. 5. Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

**Received: 24 January 2020 Accepted: 16 April 2020**

**Published online: 25 April 2020**

**References**

1. Qavi A, Garg RK, Malhotra HS, Jain A, Kumar N, Malhotra KP, et al. Disseminated cysticercosis: clinical spectrum, vol. 39; 2016. (August).

2. Reddy DS, Volkmer R II. Neurocysticercosis as an infectious acquired epilepsy worldwide. Seizure Eur J Epilepsy. 2017;52:176–81. Available from: https://doi.org/10.1016/j.seizure.2017.10.004.
3. Torgerson PR, Devleesschauwer B, Praet N, Speybroeck N, Willingham AL, Kasuga F, et al. World Health Organization Estimates of the Global and Regional Disease Burden of 11 Foodborne Parasitic Diseases, 2010: A Data Synthesis. PLoS Med. 2015;12(12):e1001920 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26633705.

4. Coral-Almeida M, Gabriël S, Abathi EN, Praet N, Benitez W, Dorny P. Taenia solium human cysticercosis: A systematic review of sero-epidemological data from endemic zones around the world. PLoS Negl Trop Dis. 2015;9(7):1–20.

5. Amienie H, Id N, Winkler AS, Braae UC, Mdiegela H, Mikiasu EM, et al. Taenia solium taeniosis and cysticercosis literature in Tanzania provides research evidence justification for control : A systematic scoping review; 2019. p. 1–17.

6. Prasad R, Kapoor K, Mishra D. Disseminated Cysticercosis in a Child, vol. 79; 2012. p. 1389–91.

7. Singh UK, Prasad R, Bhusan P, Mishra OP. Disseminated cysticercosis with a right common femoral vein thrombosis; 2013. p. 3–6.

8. Heller T, Wallrauch C, Kaminski D, Phiri S. Case Report: Cysticercosis: Sonographic Diagnosis of a Treatable Cause of Epilepsy and Skin Nodules. Am J Trop Med Hyg. 2017;97(6):1827–9.

9. Qavi A, Garg RK, Malhotra HS, Jain A, Kumar N, Malhotra KP, et al. Disseminated cysticercosis. Medicine (Baltimore). 2016;95(39):e4882 Available from: http://insights.ovid.com/crossref?an=00005792-201609270-00032.

10. Duvgnaud A, Receveur M-C, Pistone T, Malvy D. Disseminated cysticercosis revealed by subcutaneous nodules in a migrant from Cameroon. Travel Med Infect Dis. 2014;12(5):551–2 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1477893914001318.

11. Schmidt V, Kositz C, Herbinger K, Carabin H, Ngowi B, Naman E, et al. Association between Taenia solium infection and HIV / AIDS in northern Tanzania : a matched cross sectional-study. Infect Dis Poverty. 2016;1:15. Available from: https://doi.org/10.1186/s40249-016-0209-7.

12. Vazquez OH, Romo ML. Neurocysticercosis and HIV Infection : what can we learn from the published literature ? 2019;December 2018):357–365.

13. Sgadari C, Monini P, Barilliari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol. 2003;4(9):537–47 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12965274.

14. Gantt S, Cattamanchi A, Krantz E, Magaret A, Selke S, Kuntz SR, et al. Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol. 2014;60(2):127–32 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1386653214000948.

15. Mascaro C, Noormahomed EV, Mauae MN, Buene T, Funzano CA, Benson CA. A Cross-sectional Serological Study of Cysticercosis, Schistosomiasis, Toxocariasis and Echinococcosis in HIV-1 Infected People in Beira, Mozambique. PLoS Negl Trop Dis. 2014;8(9):e3121.

16. Raether W, Hanel H. Epidemiology, clinical manifestations and diagnosis of zoonotic cestode infections: an update. Parasitol Res [Internet]. 2003;91(5):412–38 Available from: http://link.springer.com/10.1007/s00436-003-0903-9.

17. Eberhard ML, Thiele EA, Yembo GE, Yibi MS, Cama VA, Ruiz-Tiben E. Case report: thirty-seven human cases of sparganosis from Ethiopia and South Sudan caused by spirurmeta Sp. Am J Trop Med Hyg. 2015;93(2):350–5.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedicentral.com/submissions